Blog

Breakthrough Glaucoma Treatments Offer New Hope for Patients Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. For years, treatment options were limited to eye drops, laser therapy, and invasive surgeries. However, recent advancements in medical science are revolutionizing how we manage this condition. Today, breakthrough glaucoma treatments […]

Open Angle Glaucoma Clinical Trials 2025: FDA, EMA, and NICE Approvals Open-angle glaucoma (OAG) remains one of the leading causes of irreversible blindness worldwide. With an aging population and increasing prevalence, the demand for innovative treatments is higher than ever. The year 2025 is poised to be a landmark period for OAG clinical trials, with

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops and invasive surgeries, have limitations, including side effects and variable efficacy. However, recent advancements in medical technology are paving the way for minimally invasive glaucoma treatments (MIGS) that promise

Revolutionizing Glaucoma Treatment with Adaptive Trials and Patient Focus Glaucoma, a leading cause of irreversible blindness worldwide, has long been a challenge for both patients and healthcare providers. Traditional treatment approaches often follow a one-size-fits-all model, which may not account for individual patient variability. However, the future of glaucoma management is evolving with adaptive clinical

MINIject® Shows 5-Year Efficacy in Glaucoma Treatment Introduction Glaucoma is a leading cause of irreversible blindness worldwide. Managing it can be challenging, especially with treatments that require daily eye drops or invasive surgery. A promising solution is the MINIject® implant, which has shown sustained results over five years in the STAR-GLOBAL trial. This long-term data

Perfuse Therapeutics to Present PER-001 Glaucoma Implant at ARVO Perfuse Therapeutics, a biotech company focused on advanced eye treatments, is set to present its new PER-001 glaucoma implant at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. This marks an important step in developing better, long-lasting solutions for glaucoma patients. Why

Pilocarpine Eye Drops Improve Outcomes After Kahook Dual Blade Goniotomy Introduction Glaucoma is a leading cause of irreversible blindness worldwide. Minimally invasive glaucoma surgeries (MIGS), such as the Kahook Dual Blade (KDB) goniotomy, effectively lower intraocular pressure (IOP). Recent studies show that combining KDB with pilocarpine eye drops can further enhance surgical outcomes. This article

Sanoculis Secures CE Mark for Innovative Glaucoma Treatment Device Introduction Sanoculis has achieved a major milestone by obtaining the CE Mark for its groundbreaking glaucoma treatment device. This approval enables the company to commercialize the technology across Europe, offering new hope to patients facing this sight-threatening condition. Glaucoma is a leading cause of irreversible blindness,